12,231 results match your criteria Hyperlipoproteinemia


Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling.

Clin Biochem 2018 Jun 18. Epub 2018 Jun 18.

Departments of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, RB 9700, The Netherlands.

Objective: Familial dysbetalipoproteinemia (FD) or Type III hyperlipoproteinemia is closely associated with the ε2ε2 genotype of the common APOE polymorphism although not all ε2 homozygotes develop FD indicating that additional factors play a role including insulin resistance (IR). The current study was undertaken to explore relationships and influences among factors, especially IR, that might elucidate FD progression pathways.

Methods: Bayesian network (BN) modeling, a probabilistic graphical exploratory data analysis tool that portrays relationships and influences among variables as simple diagrams, was applied to 52 e2e2 subjects. Read More

View Article

Expression of the Marburg I Single Nucleotide Polymorphism (MI-SNP) and the Marburg II Single Nucleotide Polymorphism (MII-SNP) of the Factor VII-Activating Protease (FSAP) Gene and Risk of Coronary Artery Disease (CAD): A Pilot Study in a Single Population.

Med Sci Monit 2018 Jun 21;24:4271-4278. Epub 2018 Jun 21.

Department of Cardiology, Hospital Bad Homburg Internal Medicine I, Bad Homburg, Germany.

BACKGROUND Factor VII-activating protease (FSAP) has a role in vascular inflammation and may have a role coronary artery disease (CAD). The aim of this study was to investigate the association between two naturally occurring single nucleotide polymorphisms (SNPs) in the FSAP gene and the risk of coronary artery disease (CAD). MATERIAL AND METHODS Of 733 patients, 173 patients had symptoms of angina, and 560 patients had CAD confirmed by coronary angiography. Read More

View Article

Severe hypertriglyceridemia presenting as eruptive xanthomatosis.

J Family Med Prim Care 2018 Jan-Feb;7(1):267-270

Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Eruptive xanthomatosis is described as the sudden eruption of erythematous yellow papules in the presence of hypertriglyceridemia, often associated with serum triglyceride levels above 2000 mg/dl. Severe hypertriglyceridemia can be caused by primary genetic mutations, secondary chronic diseases, or a combination of both. Uncontrolled diabetes mellitus is a known risk factor. Read More

View Article
June 2018
1 Read

The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.

Expert Rev Cardiovasc Ther 2018 Jun 22:1-10. Epub 2018 Jun 22.

b Akcea Therapeutics , Cambridge , MA , USA.

Background: Volanesorsen, an investigational inhibitor of apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by marked chylomicronemia leading to a spectrum of symptoms, including recurrent abdominal pain and episodes of potentially fatal acute pancreatitis (AP).

Objective: To determine the effect of volanesorsen on burden of disease on patients with FCS Methods: ReFOCUS was a retrospective global web-based survey open to patients with FCS who received volanesorsen for ≥3 months in an open-label extension study. The survey included questions about patients' experiences before and after volanesorsen treatment. Read More

View Article

Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span.

J Clin Lipidol 2018 Apr 27. Epub 2018 Apr 27.

FCS Foundation, San Diego, CA, USA.

Background: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder with loss of function mutations of lipoprotein lipase resulting in hypertriglyceridemia and accumulation of chylomicrons in plasma, often leading to acute pancreatitis. The mainstay of treatment is a specialized very-low-fat diet. Even adhering to the diet, some patients may experience high triglycerides and pancreatitis. Read More

View Article
April 2018
1 Read

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.

J Clin Lipidol 2018 Apr 26. Epub 2018 Apr 26.

Division of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by a deficiency of lipoprotein lipase leading to extreme hypertriglyceridemia. Patients' burden of illness and quality of life have been poorly addressed in the literature.

Objective: To understand the ways in which FCS impacts patients' lives. Read More

View Article
April 2018
1 Read

PCSK9: From Basic Science Discoveries to Clinical Trials.

Circ Res 2018 May;122(10):1420-1438

From the Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland.

Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now common parlance among scientists and clinicians interested in prevention and treatment of atherosclerotic cardiovascular disease. What makes this story so special is not its recent discovery nor the fact that it uncovered previously unknown biology but rather that these important scientific insights have been translated into an effective medical therapy in record time. Indeed, the translation of this discovery to novel therapeutic serves as one of the best examples of how genetic insights can be leveraged into intelligent target drug discovery. Read More

View Article

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

J Clin Lipidol 2018 Apr 4. Epub 2018 Apr 4.

Lipidology Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, Saguenay, Québec, Canada.

Background: Familial chylomicronemia syndrome (FCS) is an ultra-rare phenotype that is usually caused by biallelic mutations in the LPL gene encoding lipoprotein lipase, or less often in APOC2, APOA5, LMF1, or GPIHBP1 genes encoding cofactors or interacting proteins.

Objectives: We evaluated baseline phenotypes among FCS participants in a phase 3 randomized placebo-controlled trial of volanesorsen (NCT02211209).

Methods: Baseline clinical, fasting, and postfat load metabolic markers were assessed. Read More

View Article
April 2018
1 Read

Xanthoma Striatum Palmare.

N Engl J Med 2018 May;378(19):e26

Klinikum der Universität München, Munich, Germany

View Article

High red cell distribution width at the time of ST segment elevation myocardial infarction is better at predicting diastolic than systolic left ventricular dysfunction: A single-center prospective cohort study.

Medicine (Baltimore) 2018 May;97(18):e0601

Faculty of Medicine, "J.J. Strossmayer" University of Osijek, Osijek.

Multiple studies have demonstrated the association of red cell distribution width (RDW) with the ultrasound parameters of both systolic and diastolic heart dysfunction. We aimed to further investigate the clinical associations of RDW in the setting of ST-elevation myocardial infarction (STEMI) and to comparatively evaluate its predictive properties regarding systolic and diastolic dysfunction.A total of 89 patients with STEMI were prospectively analyzed. Read More

View Article

Role of sEH R287Q in LDLR expression, LDL binding to LDLR and LDL internalization in BEL-7402 cells.

Gene 2018 Aug 14;667:95-100. Epub 2018 Apr 14.

Department of Atherosclerosis, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital Affiliated with Capital Medical University, Beijing, China. Electronic address:

Objectives: Familial hypercholesterolemia (FH) is an autosomal dominant disorder of cholesterol metabolism. Three recognized genes (LDLR, APOB and PCSK9) present in only 20-30% of patients with possible FH cases. Additional FH-causing genes need to be explored. Read More

View Article
August 2018
1 Read

Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial.

J Clin Endocrinol Metab 2018 Jun;103(6):2403-2407

Division of Nutrition and Metabolic Diseases, Department of Internal Medicine and the Center for Human Nutrition, UT Southwestern Medical Center, Dallas, Texas.

Context: Patients with type 1 hyperlipoproteinemia (T1HLP), a rare genetic disorder, have extreme chylomicronemia and recurrent episodes of acute pancreatitis. Currently, the only therapeutic option is to consume an extremely low-fat diet because the triglyceride-lowering medications are not efficacious.

Objective: To determine the efficacy of orlistat, a gastric and pancreatic lipase inhibitor, in reducing serum triglyceride levels in patients with T1HLP. Read More

View Article

Familial Hypercholesterolemia: Nip the Evil in the Bud.

Indian J Pediatr 2018 05 29;85(5):331-332. Epub 2018 Mar 29.

Division of Genetics, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.

View Article
May 2018
2 Reads

[Aortic diseases : Modern diagnostic and therapeutic strategies].

Authors:
R Erbel

Herz 2018 May;43(3):275-290

Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

Aortic diseases include not only the thoracic but also the abdominal part of the aorta. In the etiology cardiovascular risk factors, such as hypertension, smoking and hyperlipoproteinemia play a major role, but more and more genetic diseases with familiar predisposition are being identified. Even large aneurysms remain asymptomatic as long as other organs in the neighborhood are not damaged and no acute aortic event occurs including aortic dissection, intramural hematoma, penetrating aortic ulcer, and traumatic aortic injury. Read More

View Article

[Prevalence and clinical features of familial hypercholesterolemia in Chinese patients with myocardial infarction].

Zhonghua Xin Xue Guan Bing Za Zhi 2018 Feb;46(2):109-113

Division of Dyslipidemia, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China.

To analyze the prevalence and clinical features of familial hypercholesterolemia (FH) in Chinese patients with myocardial infarction (MI). This retrospective study recruited a total of 2 119 consecutive patients (age (56.7±10. Read More

View Article
February 2018

[Prevalence and clinical characteristics of familial hypercholesterolemia among Chinese patients undergoing coronary angiography due to angina-like chest pain].

Zhonghua Xin Xue Guan Bing Za Zhi 2018 Feb;46(2):104-108

Division of Dyslipidemia, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China.

To investigate the prevalence rate and clinical characteristics of familial hypercholesterolemia (FH) in Chinese patients undergoing coronary angiography due to angina-like chest pain. From March 2011 to December 2016, a total of 9 908 consecutive patients undergoing coronary angiography in Fuwai Hospital due to angina-like chest pain were enrolled. The age of enrolled patients was (56. Read More

View Article
February 2018

Evolution from one autoimmune disorder to another. Epitope spreading?

Scand J Immunol 2018 05 25;87(5):e12657. Epub 2018 Mar 25.

Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

View Article
May 2018
3 Reads

The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention.

Curr Pediatr Rev 2017 ;13(4):260-264

Department of Medicine, McGill University, Montreal, Quebec, Canada.

Familial hypercholesterolemia (FH) is a worldwide common autosomal inherited condition associated with premature cardiovascular diseases, both in men and in women (World frequency has been recently estimated to be as high as 1:250). Identifying FH cases early in life could represent a cornerstone to prevent fatal events in adult's life. Pediatricians are well positioned to evaluate the familial cardiovascular risk factors among their young patients, to make a diagnosis and to perform familial screening. Read More

View Article
April 2018
1 Read

The prevalence and etiology of extreme hypertriglyceridemia in children: Data from a tertiary children's hospital.

J Clin Lipidol 2018 Mar - Apr;12(2):305-310. Epub 2018 Jan 12.

Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, Center for Human Nutrition, UT Southwestern Medical Center, Dallas, TX, USA.

Background: Extreme hypertriglyceridemia (eHTG; serum triglycerides ≥ 2000 mg/dL) poses a significant risk for acute pancreatitis. There is paucity of data regarding the prevalence and etiology of eHTG in children.

Objective: To determine the prevalence, clinical features and etiologies of patients with eHTG at a tertiary children's hospital in the United States and in the United States National Health and Nutrition Examination Survey (NHANES). Read More

View Article
January 2018
3 Reads

A keen eye for risk.

BMJ 2018 02 1;360:j5884. Epub 2018 Feb 1.

British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

View Article
February 2018

Detection of Familial Hypercholesterolemia Using Next Generation Sequencing in Two Population-Based Cohorts.

Chonnam Med J 2018 Jan 25;54(1):31-35. Epub 2018 Jan 25.

Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea.

We aimed to evaluate the prevalence of familial hypercholesterolaemia (FH) in a subject with hypercholesterolaemia from two population-based cohorts in South Korea. A total of 283 subjects with total cholesterol levels of 290 mg/dL (7.5 mmol/L) or higher were selected from the Namwon and Dong-gu Studies. Read More

View Article
January 2018

Type V hypertriglyceridemia in children, a therapeutic challenge in pediatrics: A case report and a review of the literature.

Medicine (Baltimore) 2017 Dec;96(51):e8864

Department of Pediatrics I, University of Medicine and Pharmacy Tirgu Mureş, Romania.

Rationale: Hypertriglyceridemia is defined as a level of triglycerides above 150 mg/dL. The complex causes and classification of hypertriglyceridemia lead to difficulties in the diagnosis and management of this condition.

Patient Concerns: We present the case of a 15 years and 6 months old female teenager, admitted in our clinic for the following complaints: severe abdominal pain predominantly in the lateral left quadrant, nausea, vomiting, and the lack of stools for 2 days. Read More

View Article
December 2017
4 Reads

A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.

CEN Case Rep 2018 May 22;7(1):127-131. Epub 2018 Jan 22.

Sanko Clinic, Fukuoka, Japan.

Lipoprotein glomerulopathy (LPG) is a rare inherited disease characterized by histopathological features of lipoprotein thrombi in dilated glomerular capillaries and type III like hyperlipoproteinemia with heterozygous mutation of the apolipoprotein (apo) E gene. We herein present the case of a 50-year-old woman with LPG complicated by neurofibromatosis type 1 (NF1). To the best of our knowledge, this is the first report of a case of LPG complicated by NF1. Read More

View Article
May 2018
1 Read

Learning From Patients With Ultrarare Conditions: Cholesterol Hoof Beats.

Authors:
Robert A Hegele

J Am Coll Cardiol 2018 Jan;71(3):289-291

Department of Medicine and Robarts Research Institute, Western University, London, Ontario, Canada. Electronic address:

View Article
January 2018

Integrated lipid clinics for adults and children with familial hypercholesterolaemia.

BMJ 2018 01 15;360:k75. Epub 2018 Jan 15.

Royal Free Hospital, London NW3 2QG, UK.

View Article
January 2018
1 Read

Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.

Circ Cardiovasc Qual Outcomes 2018 Jan;11(1):e003939

From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Dr Doshi, J.T. Puckett, Dr Parmacek, and Dr Rader) and the Leonard Davis Institute of Health Economics, Philadelphia (Dr Doshi).

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an innovative treatment option for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require further lowering of low-density lipoprotein cholesterol. However, the high costs of these agents have spurred payers to implement utilization management policies to ensure appropriate use. We examined prior authorization (PA) requirements for PCSK9is across private and public US payers. Read More

View Article
January 2018
1 Read

Molecular analysis of three known and one novel LPL variants in patients with type I hyperlipoproteinemia.

Nutr Metab Cardiovasc Dis 2018 Feb 22;28(2):158-164. Epub 2017 Nov 22.

Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden. Electronic address:

Background And Aims: Type I hyperlipoproteinemia, also known as familial chylomicronemia syndrome (FCS), is a rare autosomal recessive disorder caused by variants in LPL, APOC2, APOA5, LMF1 or GPIHBP1 genes. The aim of this study was to identify novel variants in the LPL gene causing lipoprotein lipase deficiency and to understand the molecular mechanisms.

Methods And Results: A total of 3 individuals with severe hypertriglyceridemia and recurrent pancreatitis were selected from the Lipid Clinic at Sahlgrenska University Hospital and LPL was sequenced. Read More

View Article
February 2018
3 Reads

DYNAMIC RETINA VESSEL COLOR CHANGE DURING OCULAR COMPRESSION IN SEVERE LIPEMIA RETINALIS.

Retin Cases Brief Rep 2017 Dec 27. Epub 2017 Dec 27.

Austin Retina Associates, Austin, Texas.

Purpose: The aim of this study was to describe dynamic color change in retinal vessels from white to coral pink due to externally applied ocular pressure in a 6-week-old infant with lipemia retinalis secondary to type 1b familial hyperlipoproteinemia.

Methods: Fundus images and fluorescein angiogram were taken with RetCam3 camera. Color photographs of pooled blood were taken during phlebotomy. Read More

View Article
December 2017
4 Reads

Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.

Clin Cardiol 2017 Dec 14;40(12):1291-1296. Epub 2017 Dec 14.

Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Background: Data on treatment results of lipid-lowering therapy (LLT) in familial hypercholesterolemia (FH) are limited, particularly in Asian patients.

Hypothesis: We sought to evaluate the target achievement rate and associated variables in Korean patients with FH after maximal statin-based LLT.

Methods: We enrolled 146 patients with heterozygous FH, and 90 patients were finally analyzed. Read More

View Article
December 2017
9 Reads

PCSK9 Inhibitors Show Value for Patients and the US Health Care System.

Value Health 2017 12 17;20(10):1270-1278. Epub 2017 Jun 17.

Schaeffer Center for Health Policy and Economics, University of Southern California Price School and School of Pharmacy, Los Angeles, CA, USA.

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were approved by the US Food and Drug Administration (FDA) as cholesterol-lowering therapies for patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease.

Objectives: To estimate the long-term health and economic value of PCSK9 inhibitors for Americans (51 years and older).

Methods: We conducted simulations using the Future Elderly Model, an established dynamic microsimulation model to project the lifetime outcomes for the US population aged 51 years and older. Read More

View Article
December 2017
3 Reads

A novel indel variant in LDLR responsible for familial hypercholesterolemia in a Chinese family.

PLoS One 2017 11;12(12):e0189316. Epub 2017 Dec 11.

Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.

Familial hypercholesterolemia (FH) is an inherited disorder characterized by elevation of serum cholesterol bound to low-density lipoprotein. Mutations in LDLR are the major factors responsible for FH. In this study, we recruited a four-generation Chinese family with FH and identified the clinical features of hypercholesterolemia. Read More

View Article
January 2018
15 Reads

[Hyperlipoprotienemias and (not only) atherosclerosis: fragments from history and present].

Authors:
Richard Češka

Cas Lek Cesk 2017 ;156(6):303-307

The examples from the history, as well as the recent view, clearly demonstrate a great change in the perception of hyperlipoprotienemias and dyslipidemias (HLP and DLP) at the end of 20th and at the beginning of 21st century. Our aim is not a complex overview about HLP and DLP. We just want to describe the changing position and importance of these diseases in clinical medicine. Read More

View Article
January 2017
1 Read

[Nephrotic syndrome and microhematuria in a patient with nutcracker syndrome: Report of a case and review of the literature].

Internist (Berl) 2018 06;59(6):608-614

Klinik für Gastroenterologie und Diabetologie, Vivantes Humboldt-Klinikum, Am Nordgraben 2, 13509, Berlin, Deutschland.

We report about a 43-year-old woman with polyvalent drug addiction (i.e. alcohol, nicotine, methadone maintenance program with parallel consumption of heroin) who presented to the emergency department with peripheral edema, generalized weakness, and arthralgia. Read More

View Article
June 2018
8 Reads

Persistent High Non-High-Density Lipoprotein Cholesterol in Early Childhood: A Latent Class Growth Model Analysis.

J Pediatr 2017 Dec;191:152-157

Pediatrics Outcomes Research Team (PORT), The Hospital for Sick Children, Toronto, Ontario; Faculty of Medicine, University of Toronto, Toronto, Ontario; Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario; Division of Pediatric Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario. Electronic address:

Objectives: To examine patterns of non-high-density lipoprotein (HDL) cholesterol in early childhood and identify factors associated with persistent high non-HDL cholesterol in healthy urban children.

Study Design: We identified all children enrolled in a primary care practice-based research network called TARGet Kids! (The Applied Research Group for Kids) with ≥3 laboratory measurements of non-HDL cholesterol. Latent class growth model analysis was performed to identify distinct trajectory groups for non-HDL cholesterol. Read More

View Article
December 2017
5 Reads

Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.

J Manag Care Spec Pharm 2017 Dec 25;23(12):1270-1276. Epub 2017 Sep 25.

2 Amgen, Thousand Oaks, California.

Background: Ezetimibe is recommended by clinical practice guidelines as a second-line therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, but little is known about its use and effectiveness in real-world populations.

Objective: To understand the real-world impact of adding or switching to ezetimibe on LDL-C goal achievement in patients with clinical atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH).

Methods: Patients aged ≥ 18 years with an LDL-C measurement available between January 1, 2013, and June 30, 2014, were identified using the Inovalon MORE database; this included commercial, health insurance exchange, Medicare Advantage, and managed Medicaid patients. Read More

View Article
December 2017
3 Reads

Chewing the Fat: A Case Report of Therapeutic Plasma Exchange in Hypertriglyceridemia-Induced Pancreatitis.

Hawaii J Med Public Health 2017 Nov;76(11 Suppl 2):13-15

Tripler Army Medical Center, Honolulu, HI 96859.

Hypertriglyceridemia is the third most common etiology of acute pancreatitis, but lacks a clear, evidence-based treatment approach. We present the case of a 25-year-old man who was admitted eleven times over seven years for hypertriglyceridemia-induced pancreatitis. In his first ten admissions, he received conservative therapy. Read More

View Article
November 2017

Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.

Clin Biochem 2018 Feb 20;52:67-72. Epub 2017 Nov 20.

Department of Endocrinology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands.

Objective: Familial dysbetalipoproteinemia (FD) or Type III hyperlipoproteinemia is a mixed hyperlipidemia closely associated with the ε2ε2 genotype of the common APOE polymorphism although not all homozygotes progress to FD. Unlike the polymorphism, few studies explore effects of apolipoprotein E (apoE) blood levels on FD development. Likewise, despite the known apoE2 lipoprotein binding preference for high-density lipoprotein (HDL); little work exists exploring HDL in FD. Read More

View Article
February 2018
2 Reads

Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy.

World J Gastroenterol 2017 Oct;23(40):7332-7336

Division of Gastroenterology and Liver Disease, Department of Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH 44106, United States.

Hypertriglyceridemic pancreatitis (HTGP) accounts for up to 10% of acute pancreatitis presentations in non-pregnant individuals and is the third most common cause of acute pancreatitis after alcohol and gallstones. There are a number of retrospective studies and case reports that have suggested a role for apheresis and insulin infusion in the acute inpatient setting. We report a case of HTGP in a male with hyperlipoproteinemia type III who was treated successfully with insulin and apheresis on the initial inpatient presentation followed by bi-monthly outpatient maintenance apheresis sessions for the prevention of recurrent HTGP. Read More

View Article
October 2017
4 Reads

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

Atheroscler Suppl 2017 Nov 1;30:44-49. Epub 2017 Jun 1.

Department of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany.

According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. Read More

View Article
November 2017
1 Read

Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.

Atheroscler Suppl 2017 Nov 3;30:246-252. Epub 2017 Jun 3.

Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Electronic address:

Objectives: Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing to premature and progressive CV events. Lipoproteinapheresis (LA) is the only efficacious therapy for reducing Lp(a). Data comparing the clinical efficacy of LA with respect to reduction of CV events in subjects with elevated Lp(a) versus LDL-C versus both disorders is scarce. Read More

View Article
November 2017

Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.

Atheroscler Suppl 2017 Nov;30:209-216

Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany.

Introduction: Lipoprotein apheresis (LA) represents the only effective therapeutic option for patients with elevated Lipoprotein(a) (Lp(a)) levels. We aimed at analyzing the Lp(a) reduction, rebound rates as well as mean interval values between two weekly apheresis sessions, since this might be important for the prediction of the residual cardiovascular risk and development of individualized approaches for this special therapeutic strategy.

Materials And Methods: 20 patients under weekly and 2 patients under twice weekly apheresis were included. Read More

View Article
November 2017
1 Read

Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.

Atheroscler Suppl 2017 Nov;30:200-208

Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany.

Background And Aims: Dyslipidaemias are associated with cardiovascular mortality and morbidity, driven by unstable atherosclerotic plaques with inflammatory infiltrates. Levels of messenger RNA (mRNA) for pro-inflammatory cytokines have been positively correlated with atherosclerotic disease progression. Therapeutic lipoprotein apheresis (LA) reduces plasma lipid levels and reduces inflammation. Read More

View Article
November 2017
2 Reads

Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids.

Atheroscler Suppl 2017 Nov 3;30:193-199. Epub 2017 Jun 3.

Medical Department, Division of Hepatology and Gastroenterology (Including Metabolic Diseases), Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany; Medical Department, Division of Gastroenterology, Oncology, Hematology, Rheumatology and Diabetes, Ruppiner Kliniken, Brandenburg Medical School, Neuruppin, Germany; Experimental and Clinical Research Centre, Charité University Medicine, Campus Buch, Berlin, Germany. Electronic address:

Lipoprotein apheresis has been shown to improve the cardiovascular outcome in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). An elevated intake of omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has also been associated with a reduced cardiovascular risk. However, until now only little is known about the effect of apheresis treatment on the levels of omega-6 and omega-3 polyunsaturated fatty acids (n-6 PUFA and n-3 PUFA) in patients. Read More

View Article
November 2017
2 Reads

Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.

Atheroscler Suppl 2017 Nov 31;30:187-192. Epub 2017 May 31.

Cardiology Research Center, 3rd Cherepkovskaya Street, 15a, 121552, Moscow, Russia. Electronic address:

Objective: To evaluate the association of lipoprotein(a) [Lp(a)] level with short- and long-term outcomes after coronary artery bypass grafting (CABG) and to assess the effect of a 12 month course of weekly lipoprotein apheresis on vein graft patency and coronary atherosclerosis course in post-CABG patients with hyperlipidemia.

Methods: This study was performed in patients after successful CABG and consisted of three parts: a) a retrospective part with computed tomography assessment of vein graft patency in patients with first-year recurrence of chest pain after CABG (n = 102); b) a prospective trial with evaluation of cardiovascular outcomes during follow up time up to 15 years in relation to baseline Lp(a) levels (n = 356); c) an 12-months interventional controlled study in 50 patients with low-density lipoprotein cholesterol (LDL-C) levels >2.6 mmol/L prior to the operation despite statin treatment that allocated into 2 groups: active (n = 25, weekly apheresis by cascade plasma filtration (CPF) plus atorvastatin), and control (n = 25, atorvastatin alone). Read More

View Article
November 2017
6 Reads

Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.

Atheroscler Suppl 2017 Nov 1;30:180-186. Epub 2017 Jun 1.

Apherese Centrum Rostock (ACR), Nephrocare Rostock GmbH, Rostock, Germany.

Background: Dyslipidemia is a well-known risk factor for atherosclerosis and subsequent cardiovascular disease (CVD). While low density lipoprotein cholesterol (LDL-C) is well-established and taken into consideration for risk management and therapy, lipoprotein(a) is another established CVD risk factor frequently not undergoing screening due to a lack of medical treatment options. For patients suffering from CVD due to massive elevation of Lp(a) in presence of normal LDL-C levels, lipoprotein apheresis is the only available treatment option. Read More

View Article
November 2017
4 Reads

Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.

Atheroscler Suppl 2017 Nov 1;30:174-179. Epub 2017 Jun 1.

Helios Klinikum Emil von Behring, Klinik für Gefäßmedizin, Walterhöferstraße. 11, 14165 Berlin, Germany. Electronic address:

Objective: Elevated plasma levels of lipoprotein(a) [Lp(a)], referred to as lipoprotein(a)-hyperlipoproteinemia [Lp(a)-HLP], are an independent risk factor for atherosclerosis. Lipoprotein apheresis (LA) enables an effective reduction of Lp(a) plasma levels. The present study investigates the effects of LA in patients with Lp(a)-HLP and peripheral artery disease (PAD). Read More

View Article
November 2017
2 Reads

Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis.

Atheroscler Suppl 2017 Nov 31;30:159-165. Epub 2017 May 31.

3rd Department of Internal Medicine, Metabolism and Gerontology, University Hospital Hradec Králové and Medical Faculty Charles University in Hradec Králové, Czech Republic.

Oxidative stress is thought to play an important role in the pathogenesis of disorders associated with atherosclerosis. Alpha-tocopherol is considered to be an effective lipophilic antioxidant, which protects lipid membranes against peroxidation and thus prevents cell damage by reaction with free radicals. However, measurement of alpha-tocopherol concentration in serum does not reflect the content of α-tocopherol in membranes whereas erythrocyte alpha-tocopherol may be good indicator of antioxidative status. Read More

View Article
November 2017